[SCHEDULE 13G/A] Contineum Therapeutics, Inc. SEC Filing

Rhea-AI Filing Summary

Contineum Therapeutics, Inc. Schedule 13G/A filed by Perceptive Advisors LLC, Joseph Edelman and Perceptive Life Sciences Master Fund, Ltd. reports that the Master Fund directly holds 699,486 shares of Class A common stock, representing 3.2% of the outstanding class based on 21,625,223 shares. Perceptive Advisors, as investment manager, and Mr. Edelman, as managing member, each disclose the same beneficial ownership because they may be deemed to beneficially own the Master Fund's position. The filing shows no sole voting or dispositive power and only shared voting and dispositive power for the reported shares. The filing states the position was not acquired to influence control of the issuer.

Positive

• Transparent disclosure of a 699,486-share position representing 3.2% of Class A common stock
• Certifies the holdings were not acquired to change or influence control of the issuer

Negative

• None.

Insights

Securities Analyst

TL;DR: A passive disclosure of a sub-5% stake: 699,486 shares (3.2%), reported by Perceptive entities and Joseph Edelman.

The Schedule 13G/A indicates a non-control position below the 5% materiality threshold, consistent with passive investment reporting. The Master Fund holds the shares directly while Perceptive Advisors and Mr. Edelman are disclosed due to managerial relationships, resulting in shared voting and dispositive power but no sole authority. For investors, this is a transparency filing rather than a signal of control change or activist intent, as the filer certifies the position was not acquired to influence control.

Corporate Governance Expert

TL;DR: Governance implications are limited because the position is disclosed as passive with shared, not sole, authority.

The report appropriately classifies the parties and their jurisdictions and clarifies voting and dispositive arrangements. Because the stake is 3.2% and the certification denies acquisition for control purposes, there are no immediate governance or control concerns disclosed. The joint reporting reflects required attribution rules when an investment manager and principal have relationships with the holder.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 3)

Contineum Therapeutics, Inc.

(Name of Issuer)

Class A Common Stock, par value $0.001 per share

(Title of Class of Securities)

21217B100

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 21217B100

1

Names of Reporting Persons

Perceptive Advisors LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 699,486.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 699,486.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

699,486.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

3.2 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

CUSIP No. 21217B100

1

Names of Reporting Persons

Joseph Edelman

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 699,486.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 699,486.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

699,486.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

3.2 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

CUSIP No. 21217B100

1

Names of Reporting Persons

Perceptive Life Sciences Master Fund, Ltd.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 699,486.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 699,486.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

699,486.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

3.2 %

12

Type of Reporting Person (See Instructions)

CO

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Contineum Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 3565 General Atomics Court, Suite 200, San Diego, CA 92121
Item 2.
(a)	Name of person filing: The names of the persons filing this report (collectively, the "Reporting Persons") with respect to shares of Class A Common Stock, par value $0.001 per share (the "Common Stock") of Contineum Therapeutics, Inc. (the "Issuer") are: (i) Perceptive Advisors LLC ("Perceptive Advisors") (ii) Joseph Edelman ("Mr. Edelman") (iii) Perceptive Life Sciences Master Fund, Ltd. (the "Master Fund")
(b)	Address or principal business office or, if none, residence: The address of the principal business office of each of the Reporting Persons is: 51 Astor Place, 10th Floor, New York, NY 10003
(c)	Citizenship: Perceptive Advisors is a Delaware limited liability company. Mr. Edelman is a United States citizen. The Master Fund is a Cayman Islands corporation.
(d)	Title of class of securities: Class A Common Stock, par value $0.001 per share
(e)	CUSIP No.: 21217B100
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 of the cover pages to this Schedule 13G. The ownership percentages reported are based on 21,625,223 shares of Class A Common Stock outstanding as of July 31, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 8, 2025. The Master Fund directly holds 699,486 shares of Class A Common Stock. Perceptive Advisors serves as the investment manager to the Master Fund and may be deemed to beneficially own such shares. Mr. Edelman is the managing member of Perceptive Advisors and may be deemed to beneficially own such shares.
(b)	Percent of class: Perceptive Advisors: 3.2% Mr. Edelman: 3.2% Master Fund: 3.2%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: Perceptive Advisors: 0 Mr. Edelman: 0 Master Fund: 0
	(ii) Shared power to vote or to direct the vote: Perceptive Advisors: 699,486 Mr. Edelman: 699,486 Master Fund: 699,486
	(iii) Sole power to dispose or to direct the disposition of: Perceptive Advisors: 0 Mr. Edelman: 0 Master Fund: 0
	(iv) Shared power to dispose or to direct the disposition of: Perceptive Advisors: 699,486 Mr. Edelman: 699,486 Master Fund: 699,486
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Perceptive Advisors LLC

Signature:	/s/ Joseph Edelman
Name/Title:	Joseph Edelman, Managing Member
Date:	08/14/2025

Joseph Edelman

Signature:	/s/ Joseph Edelman
Name/Title:	Joseph Edelman
Date:	08/14/2025

Perceptive Life Sciences Master Fund, Ltd.

Signature:	/s/ Joseph Edelman
Name/Title:	Joseph Edelman, Managing Member
Date:	08/14/2025

FAQ

How many Contineum Therapeutics (CTNM) shares does Perceptive Life Sciences Master Fund hold?

The Master Fund directly holds 699,486 shares of Class A common stock.

What percentage of CTNM does the reported position represent?

The reported position represents 3.2% of Class A common stock based on 21,625,223 shares outstanding.

Do Perceptive Advisors or Joseph Edelman have sole voting power over the shares?

No. The filing reports 0 sole voting power and 699,486 shared voting power for each reporting person.

Was the position acquired to influence control of Contineum Therapeutics?

No. The filing includes a certification that the securities were not acquired and are not held to change or influence control of the issuer.

Where is the principal business address of the reporting persons?

The principal business office for the reporting persons is listed as 51 Astor Place, 10th Floor, New York, NY 10003.